Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 1-10 results of 74
Breast Cancer

A012103

Official Title: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy  
Study Purpose: To evaluate whether observation results in a non-inferior recurrence free survival compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pathological complete response after neoadjuvant chemotherapy with pembrolizumab 
Status: Recruiting
Gastrointestinal Cancer

A022102

Official Title: RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB FOR FIRST-LINE TREATMENT OF METASTATIC HER2-NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA
Study Purpose: To determine if overall survival (OS) is improved in patients who received mFOLFIRINOX +/- nivolumab in comparison to FOLFOX +/- nivolumab as first-line chemotherapy for metastatic gastroesophageal adenocarcinoma
Status: Recruiting
Gastrointestinal Cancer

A022106

Official Title: PHASE II/III SECOND-LINE NABPLAGEM VS. NAB-PACLITAXEL/GEMCITABINE IN BRCA1/2 OR PALB2 MUTANT METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PLATINUM)
Study Purpose: To evaluate and compare overall response rate (ORR) in patients with BRCA1/2 or PALB2 mutant pancreas cancer whose disease has progressed on front-line FOLFIRINOX treated with NABPLAGEM = nab-paclitaxel, gemcitabine, and cisplatin (arm 1) versus nab-paclitaxel and gemcitabine (arm 2)
Status: Recruiting
Brain Cancer Other Trials

A071702

Official Title: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma 
Study Purpose: To determine whether the combination of ipilimumab and nivolumab increases the tumor response rate in patients with hypermutated recurrent glioblastoma
Status: Suspended
Gastrointestinal Cancer

A092001

Official Title: PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA
Study Purpose: To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior best response rate than carboplatin, pemetrexed and bevacizumab in patients with peritoneal mesothelioma
Status: Available
Sarcoma

A092104

Official Title: A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
Study Purpose: To compare the progression free survival (PFS)  and the overall survival (OS)of olaparib plus temozolomide (Arm 1) as compared to investigator’s choice (trabectedin or pazopanib) (Arm 2) for the treatment of patients with advanced uterine leiomyosarcoma who have received two or more prior lines of therapy as determined by investigator (local site) assessment.
Status: Suspended
Head and Neck Cancer

A092105

Official Title: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Advanced Nasopharyngeal Cancer 
Study Purpose: To determine if progression-free survival is more favorable with triplet therapy combination of Cabozantinib + Nivolumab + Ipilimumab than with doublet therapy combination of Nivolumab + Ipilimumab
Status: Recruiting
Sarcoma

A092107

Official Title: A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma 
Study Purpose: Is the combination of palbociclib plus cemiplimab better than palbociclib alone in the treatment of advanced dedifferentiated liposarcoma that cannot be removed by surgery
Status: Recruiting
Gynecologic Cancer

AFT-50

Official Title: A Phase IB/II Multi-cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
Study Purpose: To evaluate the efficacy and safety of targeted agents plus cancer immune checkpoint therapy with atezolizumab for patients with recurrent and/or persistent endometrial cancer.
Status: Recruiting
Breast Cancer

Alliance A011801

Official Title: T-DM1 and Tucatinib Compared With T-DM1 Alone In Preventing Relapses In People With High Risk Her2-Positive Breast Cancer
Study Purpose: To compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib.
Status: Recruiting